{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:27:19Z","timestamp":1740126439371,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10354-023-01007-7","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T10:03:22Z","timestamp":1678874602000},"page":"287-289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alopecia associated with dimethyl fumarate treatment for multiple sclerosis"],"prefix":"10.1007","volume":"173","author":[{"given":"Ana","family":"Abi\u010di\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Adamec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-1748","authenticated-orcid":false,"given":"Mario","family":"Habek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"1007_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40265-015-0528-1","volume":"76","author":"ED Deeks","year":"2015","unstructured":"Deeks\u00a0ED. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2015;76:243\u201354.","journal-title":"Drugs"},{"key":"1007_CR2","unstructured":"European Medicines Agency. Tecfidera product\u00a0information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecfidera-epar-product-information_en.pdf. Accessed 25 Mar 2022."},{"key":"1007_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.msard.2016.03.006","volume":"7","author":"FA Losavio","year":"2016","unstructured":"Losavio\u00a0FA, Lucchini\u00a0M, De Fino\u00a0C, Mirabella\u00a0M, Nociti\u00a0V. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis. Mult Scler Relat Disord. 2016;7:68\u20139.","journal-title":"Mult Scler Relat Disord"},{"key":"1007_CR4","first-page":"555","volume":"8","author":"L di Nuzzo","year":"2014","unstructured":"di Nuzzo\u00a0L, Orlando\u00a0R, Nasca\u00a0C, Nicoletti\u00a0F. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther. 2014;8:555\u201368.","journal-title":"Drug Des Devel Ther"},{"key":"1007_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.aan4665","volume":"360","author":"MD Kornberg","year":"2018","unstructured":"Kornberg\u00a0MD, Bhargava\u00a0P, Kim\u00a0PM, et\u00a0al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360:449\u201353.","journal-title":"Science"},{"key":"1007_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/exd.14300","volume":"30","author":"TS Purba","year":"2021","unstructured":"Purba\u00a0TS, Berriche\u00a0L, Paus\u00a0R. Compartmentalised metabolic programmes in human anagen hair follicles: New targets to modulate epithelial stem cell behaviour, keratinocyte proliferation and hair follicle immune status? Exp Dermatol. 2021;30:645\u201351.","journal-title":"Exp Dermatol"},{"key":"1007_CR7","first-page":"45","volume":"42","author":"R Lipparini","year":"1965","unstructured":"Lipparini\u00a0R, Di Feliciantonio\u00a0R, Randi\u00a0V. Un caso di porfiria acuta intermittente a\u00a0manifestazioni addominali e nervose e con alopecia generalizzata reversibile. Arch Patol Clin Med. 1965;42:45\u201352.","journal-title":"Arch Patol Clin Med"},{"key":"1007_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40263-015-0299-y","volume":"30","author":"A Chan","year":"2016","unstructured":"Chan\u00a0A, de Seze\u00a0J, Comabella\u00a0M. Teriflunomide in patients with relapsing-remitting forms of multiple sclerosis. CNS Drugs. 2016;30:41\u201351.","journal-title":"CNS Drugs"},{"key":"1007_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40268-019-00286-z","volume":"19","author":"A Muehler","year":"2019","unstructured":"Muehler\u00a0A, Kohlhof\u00a0H, Groeppel\u00a0M, et\u00a0al. The selective oral Immunomodulator vidofludimus in patients with active rheumatoid arthritis: safety results from the COMPONENT study. Drugs R\u00a0D. 2019;19:351\u201366.","journal-title":"Drugs R D"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-023-01007-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10354-023-01007-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-023-01007-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T09:27:41Z","timestamp":1693819661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10354-023-01007-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":9,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1007\/s10354-023-01007-7","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"type":"print","value":"0043-5341"},{"type":"electronic","value":"1563-258X"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"3 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.\u00a0Adamec participated as a\u00a0clinical investigator and\/or received consultation and\/or speaker fees from Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva\/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, TG Pharmaceuticals. M.\u00a0Habek participated as a\u00a0clinical investigator and\/or received consultation and\/or speaker fees from Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva\/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, TG Pharmaceuticals. A.\u00a0Abi\u010di\u0107 declares that he has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}